Combined therapeutic effect and molecular mechanisms of metformin and cisplatin in human lung cancer xenografts in nude mice

Journal of Cancer Research and Therapeutics

Volumn 11, Issue 2, 2015, Pages 324-330

  Chen, Yu Qin ^a   Chen, Gang ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; lung cancer; matrix metalloproteinase 2; metformin; survivin; vascular endothelial growth factor receptor 3; vascular endothelial growth factor C

Indexed keywords

CISPLATIN; GELATINASE A; MESSENGER RNA; METFORMIN; SURVIVIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BIRC5 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; ANIMAL; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; CELL LINE, TUMOR; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; METFORMIN; MICE; MICE, NUDE; REPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937125588     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.151444     Document Type: Article

References (23)

1. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis. Oncologist 2012;17:813-22.
2. Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, et al. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Am J Respir Cell Mol Biol 2013;49:241-50.
3. Cohen V, Khuri FR. Chemoprevention of lung cancer: Current status and future prospects. Cancer Metastasis Rev 2002;21:349-62.
4. Tao R, Gong J, Luo X, Zang M, Guo W, Wen R, et al. AMPK exerts dual regulatory effects on the PI3K pathway. J Mol Signal 2010;5:1.
5. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011;331:456-61.
6. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (ERBB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009;8:88-96.
7. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009;460:103-7.
8. Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, Barassi F, et al. Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 2003;200:620-6.
9. Li HL, Ma AN. Induction of apoptosis of non-small cell lung cancer by a methylated oligonucleotide targeting survivin gene. Cancer Gene Ther 2010;17:441-6.
10. Wheatley SP, McNeish IA. Survivin: A protein with dual roles in mitosis and apoptosis. Int Rev Cytol 2005;247:35-88.
11. Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, et al. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol 2014;45:567-74.
12. Quattrini I, Conti A, Pazzaglia L, Novello C, Ferrari S, Picci P, et al. Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation. Oncol Rep 2014;31:370-5.
13. McMasters KM, Giuliano AE, Ross MI, Reintgen DS, Hunt KK, Byrd DR, et al. Sentinel-lymph-node biopsy for breast cancer-not yet the standard of care. N Engl J Med 1998;339:990-5.
14. Talvensaari-Mattila A, Paäkkö P, Hoÿhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-62.
15. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34.
16. Roomi MW, Monterrey JC, Kalinovsky T, Niedzwiecki A, Rath M. Modulation of MMP-2 and MMP-9 by cytokines, mitogens and inhibitors in lung cancer and malignant mesothelioma cell lines. Oncol Rep 2009;22:1283-91.
17. Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, et al. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther 2013;12:1605-15.
18. Esfahanian N, Shakiba Y, Nikbin B, Soraya H, Maleki-Dizaji N, Ghazi-Khansari M, et al. Effect of metformin on the proliferation, migration, and MMP-2 and-9 expression of human umbilical vein endothelial cells. Mol Med Rep 2012;5:1068-74.
19. Milewicz T, Kiaka M, Mrozinska S, Ociepka A, Krzysiek J. Metformin-new treatment strategies for gynecologic neoplasms. Przegl Lek 2013;70:81-4.
20. Liao H, Zhou Q, Gu Y, Duan T, Feng Y. Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep 2012;27:1873-8.
21. Kawanami T, Takiguchi S, Ikeda N, Funakoshi A. A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells. Oncol Rep 2012;27:867-72.
22. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: Discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009;36:S3-17.
23. Abraham J. PI3K/AKT/mTOR pathway inhibitors: The ideal combination partners for breast cancer therapies? Expert Rev Anticancer Ther 2014;11:1-18.